Trial Profile

Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPac With Standard of Care Therapy in Subjects With Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Lung cancer; Non-small cell lung cancer; Small cell lung cancer
Focus Adverse reactions; First in man
Sponsors Nanology

Most Recent Events

19 Dec 2023 Results presented in the Nanology media release.
19 Dec 2023 According to a Nanology media release, data from this trial were presented during IASLC's North American Conference on Lung Cancer in Chicago on December 2, 2023.
08 Nov 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com